Cymbalta Related Published Studies
Well-designed clinical trials related to Cymbalta (Duloxetine)
Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13-week, randomized, placebo-controlled trial. [2009.07.20]
A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. [2009.06]
Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. [2009.05.01]
Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial. [2009.05]
Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. [2009.05]
Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. [2009.04]
Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder. [2009.03]
Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. [2009.02]
Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. [2009.02]
Duloxetine: a review of its use in the treatment of generalized anxiety disorder. [2009]
An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. [2008.12]
Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. [2008.10]
Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. [2008.10]
The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder. [2008.10]
Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. [2008.09]
A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy. [2008.09]
Long-term efficacy of duloxetine in women with stress urinary incontinence. [2008.07]
Efficacy and safety of duloxetine in elderly women with stress urinary incontinence or stress-predominant mixed urinary incontinence. [2008.06.20]
Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. [2008.06]
A randomized, controlled trial of duloxetine alone vs. duloxetine plus a telephone intervention in the treatment of depression. [2008.05]
Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder. [2008.04]
Duloxetine versus placebo for the treatment of women with stress predominant urinary incontinence in Taiwan: a double-blind, randomized, placebo-controlled trial. [2008.01.25]
A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. [2008.01]
In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. [2008]
Duloxetine compared with placebo for the treatment of women with mixed urinary incontinence. [2008]
Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. [2008]
Implications of Pain in Generalized Anxiety Disorder: Efficacy of Duloxetine. [2008]
Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder. [2008]
Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. [2007.11]
A randomized, controlled trial of duloxetine alone vs. duloxetine plus a telephone intervention in the treatment of depression. [2007.09.28]
An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. [2007.09]
Duloxetine compared with placebo for treating women with symptoms of overactive bladder. [2007.08]
Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence. [2007.08]
Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression. [2007.07]
Modafinil Augmentation of Selective Serotonin Reuptake Inhibitor Therapy in MDD Partial Responders with Persistent Fatigue and Sleepiness. [2007.07]
Once-daily duloxetine 60 mg in the treatment of major depressive disorder: Multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil. [2007.06]
The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate. [2007.06]
Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. [2007.06]
Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. [2007.06]
Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. [2007.05]
Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies. [2007.04]
Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain. [2007.03]
Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. [2007.02.20]
Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. [2007.02]
Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects. [2007]
The efficacy of duloxetine in the treatment of premature ejaculation. [2007]
Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. [2007]
Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). [2007]
A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. [2006.10.24]
Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. [2006.09]
Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics. [2006.09]
Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat. [2006.09]
Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain. [2006.06]
Management of depression relapse: re-initiation of duloxetine treatment or dose increase. [2006.06]
Duloxetine 60 mg once daily in the treatment of milder major depressive disorder. [2006.05]
Economic evaluation of duloxetine for the treatment of women with stress urinary incontinence: a Markov model comparing pharmacotherapy with pelvic floor muscle training. [2006.04]
Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. [2006.04]
Duloxetine for the treatment of stress urinary incontinence in women: an integrated analysis of safety. [2006.03.01]
Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. [2006.02]
A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. [2005.12.15]
A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. [2005.09]
Impact of duloxetine on quality of life for women with symptoms of urinary incontinence. [2005.09]
Duloxetine for the treatment of major depressive disorder in women ages 40 to 55 years. [2005.07]
Duloxetine vs. placebo in patients with painful diabetic neuropathy. [2005.07]
Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. [2005.06]
A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. [2005.05]
Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. [2005.04]
Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies. [2005.03]
Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects. [2005.02]
Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. [2005.01]
Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. [2004.12]
Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. [2004.09]
A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. [2004.09]
Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus. [2004.08]
Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. [2004.08]
Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers. [2004.05]
Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. [2004.03]
Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. [2004.02]
Effects of duloxetine on painful physical symptoms associated with depression. [2004.01]
Effect of age on the pharmacokinetics of duloxetine in women. [2004.01]
Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. [2003.10]
Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study. [2003.09]
Duloxetine in treatment of anxiety symptoms associated with depression. [2003]
Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. [2002.11]
Duloxetine versus placebo in the treatment of stress urinary incontinence. [2002.07]
Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. [2002.04]
Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. [2002.03]
Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. [2001.05]
Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. [2000.02]
An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group. [1997.05]
Well-designed clinical trials possibly related to Cymbalta (Duloxetine)
Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. [2009.06]
Treatment of depression in the elderly: a review of the recent literature on the efficacy of single- versus dual-action antidepressants. [2009.05]
Effect of antidepressants on melatonin metabolite in depressed patients. [2009.05]
Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial. [2009.04.23]
Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission. [2009.02]
Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD). [2009.02]
Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. [2008.10]
The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder. [2008.09]
Minimal clinically important differences in Incontinence Quality-of-Life scores in stress urinary incontinence. [2006.06]
Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. [2005.09.20]
Cost-effectiveness inferences from bootstrap quadrant confidence levels: three degrees of dominance. [2005]
|
